Hematology/Oncology News

The addition of talazoparib to enzalutamide extended OS among men with metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 European Society for Medical Oncology Congress with a focus on leukemia.

A novel drug delivery construct may protect individuals against cisplatin-induced ototoxicity and associated hearing loss.

Karen E. Knudsen, MBA, PhD, embraced a straightforward but powerful principle when she assumed two key leadership positions with American Cancer Society.

People with MS had an increased risk for bladder, brain and cervical cancers compared with people without MS, according to a new study in Neurology, the medical journal of the American Academy of Neurology.

In this video, Douglas Tremblay, MD, discusses the results of a study into CD19-targeted chimeric antigen receptor T-cell therapy in acute lymphocytic leukemia presented at ESMO Congress 2024.

In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic myelomonocytic leukemia presented at ESMO Congress 2024.

In this video, Rosalie Griffin, PhD, discusses the results of a study into point mutations and their correlation with developing blood cancers presented at ESMO Congress 2024.

In this video, Rosalie Griffin, PhD, discusses the results of a study she presented at ESMO Congress 2024, which examined a biomarker that could indicate a person’s risk for developing blood cancer.

Immunotherapy treatment may make liver transplant viable for patients with later-stage hepatocellular carcinoma provided they adhere to a 3-month waiting period, according to study results.